Oral Drug Pairs With Immunotherapy in Melanoma Study
Patients with resectable Stage III melanoma may one day benefit, but these early results are not yet proven to help.
Updated on Nov. 3, 2026 in Cancer
Primmune Therapeutics will present two abstracts on its investigational drug polvitolimod HCl (PRTX007) at the SITC 41st Annual Meeting in Phoenix, Arizona, November 4-8, 2026. Both posters will be available on the company's website on November 7, 2026, for patients and clinicians following melanoma and immunotherapy research.
Why it matters
The presentations offer an early look at whether PRTX007, an oral immune-signaling drug, can be combined with an existing immunotherapy to help patients with resectable Stage III melanoma respond before surgery. Because the data are from an early-stage study, they signal a line of research worth watching rather than a change in how melanoma is treated today.
The INFLECTION-003 work is a Phase 2, multi-center, single-arm study in participants with resectable Stage III melanoma, while earlier safety data come from two Phase 1 studies in 118 healthy volunteers. Those Phase 1 studies reported the drug was generally well tolerated with no serious adverse events, and the Phase 2 primary objective is the major pathologic response rate.
The players
Primmune Therapeutics
A clinical-stage biotech company developing polvitolimod HCl (PRTX007), an oral TLR7 agonist prodrug being studied in immunotherapy combinations.
Society for Immunotherapy of Cancer (SITC)
The organization hosting its 41st Annual Meeting, a major gathering where researchers present cancer immunotherapy studies.
The details
PRTX007 is an orally administered, systemically acting toll-like receptor 7 agonist prodrug, designed to shift immune signaling toward an IRF7-driven interferon response and away from NF-kB-mediated inflammatory cytokine signaling. In INFLECTION-003, participants take oral PRTX007 together with intravenous pembrolizumab, an established immunotherapy, for 9 weeks before their tumor is surgically removed. Researchers then examine how much of the tumor shows a pathologic response.
Timeline
November 4-8, 2026: SITC 41st Annual Meeting in Phoenix, Arizona.
Friday, November 6, 2026: INFLECTION-003 abstract presentation, 12:15-1:45 PM and 5:30-7 PM MT.
Saturday, November 7, 2026: Prospective Phase 1 PRTX007 abstract presentation, with posters available online.
Health Landscape
Checkpoint immunotherapies such as pembrolizumab have become a standard tool in melanoma, and researchers are testing whether adding agents that prime the immune system can improve results. PRTX007 belongs to that wave of combination approaches, but its benefit has not yet been shown against standard treatment alone.
For now, this research is early and does not change current melanoma care, but it is worth knowing that clinical trials are testing new combinations alongside standard immunotherapy. If you have melanoma or a family history of it, ask your oncologist whether a clinical trial could be an option.
The takeaway
Early immunotherapy combination research like this is promising but still preliminary, so treatment decisions should stay with your oncology team. If you have questions about trial participation, bring them to your physician.
What happens next
The full INFLECTION-003 and Phase 1 poster data will become available online on Saturday, November 7, 2026, giving the research community its first detailed look at the findings.
Further reading
For broader context on how new treatments are reaching patients, explore our Cancer coverage.
More information
You can look up the study itself in the ClinicalTrials.gov registry under identifier NCT07565285.
